-
The FDA has approved the first once-daily protease inhibitor (PI) for the treatment of HIV-1 infections. Atazanavir (Bristol-Myers Squibb) is the newest PI to enter this relatively crowded class. It is marketed under the trade name Reyataz.
-
Women who survive breast cancer may be at a lower risk of developing coronary artery disease compared with women without a history of breast cancer.
-
The association of caffeine and nicotine in pharmaceutical products and aneurysmal SAH warrants further study.
-
The low-carbohydrate diet produced a greater weight loss than did the conventional diet for the first 6 months, but the differences were not significant at 1 year.
-
Peripheral arterial disease is common. Screening with measurement of the ankle-brachial index will improve detection.
-
Only about 12% of patients with new onset atrial fibrillation who did not have apparent contraindications to warfarin treatment filled prescriptions for it.
-
A Strategy to Reduce Cardiovascular Disease by More Than 80 Percent; Pearly Penile Papules: Still No Reason for Uneasiness; The Epidemiology of Major Depressive Disorder
-
A discovery that came out of a congestive heart failure (CHF) project led to a Medication Mission that is improving quality of life and reducing readmission rates for patients at St. Joseph Health Center in Warren, OH.
-
Daily bed alerts, emergency department (ED) case management, and an express admit unit for direct admits from physician offices are among the initiatives that help streamline operations at Lehigh Valley Hospital and Health Network in Allentown, PA.
-
Whether your organization is seeking to reduce process inefficiencies or eliminate the chance of unintended patient harm, action taking is a critical step in the improvement cycle. The cycle involves devising a new or improved process, implementing changes, monitoring the effects of changes, making further adjustments where necessary, and continuing to monitor.